Insulet Corp (PODD)

Health Services • Health Care

Stock AI

News & Reports

July 27, 2026 Insulet Corporation Faces Securities Class Action Amid Manufacturing Concerns Insulet Corporation is embroiled in a securities class action lawsuit filed by investors due to alleged manufacturing deficiencies in its insulin delivery products. The lawsuit claims that these issues were not disclosed, leading to inflated stock prices. Investors are urged to act before the lead plaintiff deadline on August 31, 2026.

July 16, 2026 Insulet Corp Faces Securities Fraud Class Action Lawsuit Amid Stock Turbulence Insulet Corporation is facing a class action lawsuit for securities fraud after a substantial stock decline linked to misrepresentations about the safety of its insulin delivery systems. Investors are urged to explore their legal options with Bleichmar Fonti & Auld LLP as the case unfolds in the U.S. District Court for the District of Massachusetts.

July 14, 2026 Insulet Corporation Partners with Calm to Enhance Emotional Well-Being for the Diabetes Community Insulet Corporation has partnered with Calm to launch 'The Mind in Range Collection', providing mental health resources for the diabetes community. This initiative addresses the emotional challenges faced by individuals managing diabetes, offering guided meditations and sleep stories to alleviate stress.

July 09, 2026 Insulet Corporation Faces Securities Class Action Over Alleged Misstatements Insulet Corporation is being sued for alleged misstatements regarding the safety of its Omnipod insulin delivery system, involving former COO Eric Benjamin. Investors have suffered substantial losses following critical disclosures about manufacturing flaws. This lawsuit highlights the importance of corporate accountability and accurate public disclosures.

July 08, 2026 Insulet Corporation Faces Securities Fraud Lawsuit Amid Product Safety Concerns Insulet Corporation is facing a class action lawsuit due to product safety issues related to its Omnipod devices, causing significant stock price declines. Investors are urged to act quickly as the deadline for filing a lead plaintiff motion approaches.

July 07, 2026 Insulet Corporation Faces Securities Fraud Lawsuit Amid Safety Concerns Insulet Corporation is under a class action lawsuit for securities fraud following a drop in stock price due to safety concerns with its Omnipod insulin delivery systems. Investors are encouraged to participate in the lawsuit as they seek accountability for alleged misrepresentations regarding product safety.

July 07, 2026 Insulet Corporation Faces Legal Challenges Following Product Safety Issues Insulet Corporation is facing a class action lawsuit due to serious product safety concerns regarding its insulin delivery systems. Investors who purchased shares between February 21, 2025, and May 26, 2026, are urged to take action by the August 31, 2026, deadline. The lawsuit alleges misleading statements and defective manufacturing practices.

July 06, 2026 Securities Class Action Filed Against Insulet Corporation: A Closer Look A class action lawsuit has been filed against Insulet Corporation for allegedly misleading investors about its manufacturing controls, leading to significant stock price declines. Investors affected during the Class Period should consider applying for lead plaintiff status before the August 31, 2026 deadline.

July 06, 2026 Insulet Corporation Faces Class Action Lawsuit Amid Securities Fraud Allegations Insulet Corporation is facing a class action lawsuit after announcing serious product safety issues affecting its Omnipod devices. Shareholders are urged to act by August 31, 2026, amid allegations of misleading statements from the company's executives that may have inflated stock prices and concealed operational risks.

July 06, 2026 Insulet Corp Expands Global Reach with Launch of Omnipod® 5 and Omnipod Discover™ in Spain Insulet Corporation has launched the Omnipod® 5 and Omnipod Discover™ in Spain, marking a milestone in diabetes management for millions. These products aim to simplify insulin delivery and improve users' quality of life, demonstrating Insulet's commitment to global diabetes care.

July 05, 2026 Insulet Corporation Faces Class Action Lawsuit Over Alleged Misleading Statements Insulet Corporation is facing a class action lawsuit over claims of misleading statements about its product safety and manufacturing processes. Shareholders affected by the alleged operational shortcomings are invited to participate, potentially recovering losses without financial risk.

July 03, 2026 Insulet Corporation Faces Class Action Lawsuit Over Alleged Securities Fraud Insulet Corporation is facing a class action lawsuit for allegedly misleading investors about its manufacturing processes, leading to financial losses. The lawsuit, initiated by the Schall Law Firm, invites affected shareholders to participate before the August 31 deadline.

July 02, 2026 Insulet Corporation Faces Class Action Lawsuit Amid Manufacturing Concerns Insulet Corporation is under scrutiny due to a class action lawsuit following significant stock declines linked to manufacturing issues with its Omnipod products. Allegations include defective manufacturing controls and misleading statements by management, prompting investors to consider legal options before the August 31, 2026 deadline.

July 02, 2026 Insulet Corporation Faces Class Action Lawsuit Over Allegations of Misleading Investors Insulet Corporation is embroiled in a class action lawsuit claiming it misled investors about the safety of its insulin delivery products. The suit alleges defective manufacturing controls and significant stock price declines following product disclosures. Shareholders are encouraged to consider participating in the litigation.

July 01, 2026 Insulet Corporation to Reveal Second Quarter 2026 Financial Results Insulet Corporation is set to announce its Q2 2026 financial results on August 5, 2026, followed by a conference call for stakeholders. The company, known for its innovative Omnipod insulin pump technology, is expected to share insights on its performance and future growth strategies.

June 25, 2026 Insulet Corporation Welcomes Jay Mazelsky to Board of Directors Insulet Corporation has appointed Jay Mazelsky to its Board of Directors, effective July 1, 2026. His extensive experience in healthcare and innovation is expected to drive growth and enhance Insulet's leadership in diabetes management.

June 06, 2026 Insulet Corporation Unveils Promising Data for Innovative Diabetes Management Systems Insulet Corporation has unveiled promising data on its next-generation diabetes management systems, the Omnipod® 6 and FCL system, demonstrating significant improvements in glycemic control and user satisfaction. Key studies show enhanced performance and reduced insulin use, highlighting Insulet's commitment to innovation in diabetes care.

June 03, 2026 Insulet Corporation Launches Enhanced Omnipod® 5 Algorithm and Expands Sensor Compatibility Insulet Corporation has launched an enhanced algorithm for the Omnipod 5 system, now compatible with Abbott's FreeStyle Libre 3 Plus sensor. This update aims to improve diabetes management through better automation and personalization, with over-the-air updates for existing users.

May 27, 2026 Insulet Corporation Set to Shine at William Blair Growth Stock Conference Insulet Corporation will present at the William Blair Growth Stock Conference on June 3, 2026, discussing its innovative insulin delivery technology and growth strategies. The live webcast will allow stakeholders to stay informed about the company's advancements in diabetes management and beyond.

May 26, 2026 Insulet Corp Issues Voluntary Medical Device Correction for Omnipod Products Insulet Corporation announced a voluntary recall for specific lots of its Omnipod products due to a manufacturing defect that may lead to insulin under-delivery. Approximately 7 million Pods are affected, with a focus on ensuring user safety and product quality through corrective measures.

May 06, 2026 Insulet Corp Announces Strong Q1 2026 Financial Results Amid Product Innovations and International Expansion Insulet Corporation's Q1 2026 results show a notable 33.9% revenue increase, largely due to the success of the Omnipod platform and international market growth. The company remains focused on product innovation and expanding its customer base amidst rising costs.

May 06, 2026 Insulet Corporation Reports Strong First Quarter 2026 Results Insulet Corporation reported impressive Q1 2026 results with a revenue of $761.7 million, a 33.9% increase year-over-year. Key drivers included a surge in Omnipod sales and significant product innovations. The company raised its annual revenue outlook, reinforcing its leadership in diabetes management.

May 05, 2026 Insulet Corporation Publishes 2025 Sustainability Report, Showcasing Commitment to People and Planet Insulet Corporation's 2025 Sustainability Report highlights its commitment to sustainability through renewable energy usage, product recycling, and community engagement. Key achievements include expanding the Pod Recycling Program and fostering ethical sourcing practices, reflecting a mission-driven approach to both healthcare and environmental stewardship.

May 04, 2026 Insulet Corporation Takes a Major Leap Forward with EVOLVE Study for Type 2 Diabetes Insulet Corporation has initiated the EVOLVE pivotal study to assess a groundbreaking fully closed-loop automated insulin delivery system for type 2 diabetes. This innovative approach aims to improve glycemic control while minimizing user interaction, potentially transforming diabetes management for millions.

April 28, 2026 Insulet Corporation to Showcase Innovations at BofA Securities Health Care Conference Insulet Corporation will present its latest innovations, including the Omnipod® Insulin Management System, at the BofA Securities 2026 Health Care Conference. The event showcases advancements in diabetes management and the potential for broader applications of its Pod technology.

April 01, 2026 Insulet Corporation Set to Release Q1 2026 Financial Results Insulet Corporation is set to release its Q1 2026 financial results on May 6. The company will host a conference call to discuss its performance and strategic direction, particularly regarding its innovative Omnipod product line for diabetes management.

March 30, 2026 Insulet Corporation Appoints Mike Panos as Chief Commercial Officer Insulet Corporation has named Mike Panos as its new Chief Commercial Officer to drive growth in the diabetes management market. With over 30 years of experience in medical technology, Panos aims to enhance Insulet's commercial capabilities and expand market access for innovative insulin delivery solutions.

March 28, 2026 Insulet Corporation Faces Scrutiny Amid Product Recall and Shareholder Investigation Insulet Corporation is under investigation following a product recall of its Omnipod® 5 Pods, leading to a significant stock price drop. The Schall Law Firm is examining potential securities law violations that could affect investors. Shareholders may have options for collective legal action as the situation develops.

March 19, 2026 Insulet Corporation Faces Securities Fraud Investigation Following Manufacturing Disclosure Insulet Corporation is under investigation for potential securities fraud after a manufacturing issue led to a significant stock price drop. Shareholders affected by the situation are encouraged to consider legal action to recover losses.

March 18, 2026 Insulet Corporation Faces Securities Fraud Investigation Amid Product Recall Insulet Corporation is facing a securities fraud investigation following a product recall of its Omnipod® 5 Pods. The recall led to a sharp decline in stock prices, raising concerns among investors about potential financial losses and legal implications. Shareholders affected are urged to seek legal counsel.

March 13, 2026 Securities Fraud Investigation Launched Into Insulet Corporation Following Product Recall Announcement Insulet Corporation is under investigation for securities fraud following a product recall of its Omnipod® 5 Pods, raising concerns about prior disclosures. The law firm Glancy Prongay Wolke & Rotter LLP is encouraging affected shareholders to explore legal options for recovery.

March 13, 2026 Insulet Corporation Faces Securities Fraud Investigation Following Product Recall Insulet Corporation is under investigation for potential securities fraud after recalling its Omnipod® 5 Pods due to a manufacturing defect. This has raised concerns about the company's governance and impacted investor confidence, prompting legal action from affected shareholders.

March 13, 2026 Insulet Corporation Faces Securities Fraud Investigation Following Stock Decline Insulet Corporation is currently facing a securities fraud investigation following a sharp decline in its stock price due to a manufacturing issue with its Omnipod® 5 Pods. The Law Offices of Howard G. Smith are representing affected shareholders, highlighting the serious implications for product safety and investor confidence.

March 12, 2026 Insulet Corp Announces Voluntary Medical Device Correction for Omnipod® 5 Pods Insulet Corporation has initiated a voluntary Medical Device Correction for specific lots of Omnipod® 5 Pods due to a manufacturing defect that could impact insulin delivery. Users are advised to check their Pod lot numbers and discontinue use if affected. The company assures that other products remain safe and has implemented enhancements to manufacturing processes.

March 11, 2026 Insulet Corporation Announces Breakthrough Study Results for Fully Closed-Loop Insulin Delivery System Insulet Corporation has revealed groundbreaking results from its EVOLUTION 2 study, demonstrating the efficacy of a fully closed-loop insulin delivery system for adults with type 2 diabetes. The study showcased significant improvements in average time in range and user satisfaction, setting the stage for future advancements in diabetes management.

March 10, 2026 Insulet Corporation to Showcase Breakthrough Results in Diabetes Management at ATTD 2026 Insulet Corporation will present groundbreaking results for its Fully Closed-Loop insulin delivery system for Type 2 Diabetes at the ATTD 2026 conference. The EVOLUTION 2 study results highlight advancements in diabetes management, aiming to improve patient experiences and outcomes.

February 18, 2026 Insulet Corporation Reports Strong Fourth Quarter and Full Year 2025 Results Insulet Corporation achieved remarkable financial results for Q4 and the full year 2025, with revenues of $783.8 million and $2.7 billion respectively. The company continues to lead in innovation and customer trust, setting the stage for future growth in the diabetes management market.

February 18, 2026 Insulet Corp's 2025 Annual Report: A Year of Remarkable Growth and Innovation in Diabetes Management Insulet Corp's 2025 annual report highlights remarkable revenue growth, with total earnings reaching $2.7 billion, driven by the Omnipod platform. The company continues to innovate with significant advancements in insulin delivery systems while facing challenges in debt management and legal disputes.

January 06, 2026 Insulet Corp Unveils Vision for the Future of Diabetes Management at CES 2026 At CES 2026, Insulet Corporation showcased its vision for 'liveable technology' in diabetes management through the Omnipod 5 system, emphasizing user-friendly, automated care. The event highlighted the importance of emotional support and reducing cognitive burdens for individuals living with diabetes.

December 16, 2025 Insulet Corporation to Present at the 44th Annual J.P. Morgan Healthcare Conference Insulet Corporation is set to present at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its Omnipod Insulin Management System and future innovations. The company is expanding its product offerings beyond diabetes management, enhancing its role in the medical device industry.

December 04, 2025 Insulet Corp Announces FDA Clearance for Enhanced Omnipod® 5 Algorithm Insulet Corporation has received FDA clearance for significant updates to its Omnipod® 5 Automated Insulin Delivery System. The enhancements include a new 100 mg/dL target glucose setting and improved user experience, set to launch in 2026, aimed at better diabetes management for users.

November 20, 2025 Insulet Corporation Unveils Strategic Vision for 2025-2028 at Investor Day Insulet Corporation outlined its strategic vision for 2025-2028, focusing on innovation, clinical advancements, and market expansion in diabetes care. The presentation highlighted strong revenue growth projections and groundbreaking product enhancements, positioning Insulet as a leader in automated insulin delivery systems.

November 06, 2025 Insulet Corporation Reports Strong Q3 2025 Results Insulet Corporation reported impressive Q3 2025 results, showing a 29.9% revenue increase, led by strong demand for Omnipod products. The company is well-positioned for future growth with strategic partnerships and a positive outlook for the remainder of the year.

November 06, 2025 Insulet Corp Reports Strong Q3 2025 Results: Revenue Grows Nearly 30% Insulet Corp reported a 29.9% revenue increase for Q3 2025, reaching $706.3 million, bolstered by strong sales of the Omnipod insulin delivery systems. The company also expanded its international presence, launching Omnipod 5 in nine new countries. Ongoing investments in R&D reflect Insulet's commitment to innovation in diabetes management.

October 30, 2025 Insulet Corp Champions Workplace Inclusion for People with Diabetes Insulet Corporation has launched 'The Day Diabetes Showed Up to Work' campaign for Diabetes Awareness Month, focusing on the challenges faced by people with diabetes in the workplace. Key survey findings reveal significant misunderstandings and stigma, prompting Insulet to provide resources and support for employees living with diabetes.

October 23, 2025 Insulet Corporation Welcomes New Board Member: Robbie Huffines Insulet Corporation has appointed Robbie Huffines, a financial expert with extensive healthcare experience, to its Board of Directors. His strategic insights will support Insulet's growth and commitment to innovation in diabetes management.

October 10, 2025 Insulet Corporation to Host Investor Day on November 20, 2025 Insulet Corporation will host its Investor Day on November 20, 2025, at its headquarters, focusing on long-term strategies and financial outlook. The event will feature presentations from management and a live webcast for broader participation.

September 18, 2025 Insulet Corp Unveils Vibrant New Color for Omnipod: A Celebration of Community and Empowerment Insulet Corp has launched a new vibrant color for its Omnipod insulin pump, named Omnipod Mango, in partnership with Pantone. This bright hue symbolizes community and empowerment, breaking away from traditional colors in diabetes management. The initiative aims to enhance the identity and pride of users while continuing to innovate in diabetes care.

September 16, 2025 Insulet Corporation Announces Strategic CFO Transition Insulet Corporation has appointed Flavia Pease as the new CFO, taking over from Ana Maria Chadwick, who transitions to Senior Advisor. With extensive experience in financial leadership, Pease is expected to drive growth and innovation as Insulet anticipates strong third-quarter results.

August 07, 2025 Insulet Corp's Q2 2025 Report: A Surge in Revenue and Strategic Growth Initiatives Insulet Corp experienced a significant revenue surge of 32.9% in Q2 2025, reaching $649.1 million, fueled by strong U.S. sales and international market expansion. Despite rising costs and interest expenses, the company remains focused on innovation and strategic growth in diabetes management.

May 13, 2025 Insulet Corporation Publishes 2024 Sustainability Report Insulet Corporation's 2024 Sustainability Report highlights their strides in environmental and social governance. Key initiatives include renewable energy use, innovative product takeback programs, and community engagement efforts, demonstrating their commitment to sustainability and improved health outcomes.

May 09, 2025 Insulet Corp Reports Strong Q1 2025 Results: A Glimpse into Growth and Expansion Insulet Corp's Q1 2025 report reveals a remarkable 28.8% revenue growth to $569 million, fueled by increased Omnipod product sales. Despite rising expenses, the company maintains a robust cash position and aims for further market expansion.

May 08, 2025 Insulet Corporation Reports Strong Q1 2025 Results with 29% Revenue Growth Insulet Corporation reported a 29% revenue increase for Q1 2025, reaching $569 million, primarily fueled by strong Omnipod sales. The company is expanding its global presence and expects continued growth throughout the year.

April 28, 2025 Insulet Corporation Welcomes Ashley McEvoy as New CEO Insulet Corporation has appointed Ashley McEvoy as its new CEO, succeeding Jim Hollingshead. With nearly 30 years in healthcare, McEvoy aims to drive innovation and growth in diabetes care, leveraging the company's strengths for future success.

April 03, 2025 Insulet Corporation Prepares for First Quarter 2025 Financial Results Insulet Corporation will announce its Q1 2025 financial results on May 8, 2025. Following the announcement, a conference call will provide insights into the company's performance and innovations in diabetes management.

March 11, 2025 Insulet Corporation to Host Investor Day: A Deep Dive into the Future of Diabetes Management Insulet Corporation will host its Investor Day on June 5, 2025, showcasing the Omnipod 5 platform and discussing strategic priorities, market opportunities, and growth drivers in diabetes management. The event will feature key presentations from leadership and industry experts.

February 21, 2025 Insulet Corp. Reports Robust Growth in 2024 Annual Financial Results Insulet Corporation achieved a 22.1% revenue increase in 2024, reaching $2.071 billion, primarily fueled by its Omnipod product line. The company also reported a 40.1% rise in net income, reflecting strong operational performance and effective cost management.

February 20, 2025 Insulet Corporation Reports Strong Financial Performance for 2024 Insulet Corporation reported impressive financial results for 2024, achieving $2.1 billion in revenue, a 22.1% increase year-over-year. Strong demand for its Omnipod products and expansion in international markets contributed significantly to its growth. The company anticipates continued growth in 2025, with forecasted revenue growth of 16% to 20%.

January 22, 2025 SWOT Analysis of Insulet Corporation in 2025 This article provides a comprehensive SWOT analysis of Insulet Corporation in 2025, highlighting its innovative Omnipod insulin delivery systems, market strengths, and challenges. It discusses opportunities for growth and the potential threats the company faces in a competitive landscape.

November 08, 2024 Insulet Corp. Reports Strong Q3 2024 Financial Results Insulet Corp. has reported a 25.7% increase in revenue for Q3 2024, driven by strong sales of its Omnipod platform both domestically and internationally. Despite rising costs, the company maintained profitability with a net income of $77.5 million and is well-positioned for future growth despite supply chain challenges.

August 09, 2024 Insulet Corp. Reports Strong Q2 2024 Results Driven by Omnipod Growth Insulet Corp. announced a 23.2% revenue growth in Q2 2024, reaching $488.5 million, largely due to increased sales of its Omnipod platform. The company is expanding internationally and investing in R&D to enhance diabetes management solutions.

May 10, 2024 Insulet Corp. Reports Strong Q1 2024 Results: Revenue and Net Income Surge Insulet Corporation's Q1 2024 results show a 23.3% revenue increase, reaching $441.7 million, and a net income surge of 71.4%. The success is driven by the Omnipod platform and strategic acquisitions, positioning the company for continued growth in diabetes management.

Insulet Corporation to Showcase Innovations at BofA Securities Health Care Conference

Last updated: April 28, 2026 •

Taurigo

1. Introduction to the Event

Insulet Corporation (NASDAQ: PODD), a frontrunner in the development of tubeless insulin pump technologies, has announced its participation in the highly anticipated BofA Securities 2026 Health Care Conference. This event is set to take place in Las Vegas on Wednesday, May 13, 2026, at 9:20 a.m. Pacific Time.

2. Presentation Details

During the conference, Insulet's management will present insights into the company’s latest advancements, particularly focusing on its flagship product, the Omnipod® Insulin Management System. The live presentation can be accessed via a webcast, with a replay available for those unable to attend in real-time. Investors and stakeholders can find the details on Insulet's Investor Relations website.

3. About Insulet Corporation

Founded in Massachusetts, Insulet Corporation is dedicated to transforming diabetes management through innovation. The company is best known for its Omnipod product platform, which offers a unique alternative to traditional insulin delivery methods.

The Omnipod Insulin Management System

The Omnipod system features a groundbreaking design that allows for a tubeless, disposable Pod capable of delivering insulin for up to three days without the need for needles or injections. This innovative approach is especially beneficial for individuals managing diabetes, as it simplifies insulin administration and enhances the overall user experience.

The Omnipod 5 Automated Insulin Delivery System

One of Insulet's standout innovations is the Omnipod 5 Automated Insulin Delivery System. This system integrates seamlessly with continuous glucose monitors (CGMs), enabling users to manage their blood sugar levels effectively. It eliminates the inconvenience of multiple daily injections and fingerstick tests, offering a more streamlined and user-friendly solution. Additionally, the system can be controlled via a compatible personal smartphone or the Omnipod 5 Controller, further enhancing its accessibility and appeal.

4. Expanding Horizons Beyond Insulin Delivery

Insulet is not limited to insulin management; the company is actively exploring the potential of its Pod technology for the delivery of non-insulin subcutaneous drugs across various therapeutic areas. This diversification illustrates Insulet's commitment to innovation and its vision of improving patient care beyond diabetes management.

5. Conclusion

As Insulet prepares for its presentation at the BofA Securities 2026 Health Care Conference, anticipation builds around the insights and innovations the company will share. With its pioneering work in diabetes management and potential expansions into other therapeutic areas, Insulet Corporation continues to solidify its position as a leader in the medical device industry. Investors and healthcare professionals alike will be keenly watching the developments that emerge from this key event.

Original press release

You may also be interested in: